These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 36676804)

  • 1. A Real-World Cost-Effectiveness Analysis of Rivaroxaban versus Vitamin K Antagonists for the Treatment of Symptomatic Venous Thromboembolism: Lessons from the REMOTEV Registry.
    Kepka S; Cordeanu EM; Zarca K; Frantz AS; Ohlmann P; Andres E; Bilbault P; Durand-Zaleski I; Stephan D
    Medicina (Kaunas); 2023 Jan; 59(1):. PubMed ID: 36676804
    [No Abstract]   [Full Text] [Related]  

  • 2. Rivaroxaban for non-valvular atrial fibrillation and venous thromboembolism in the Netherlands: a real-world data based cost-effectiveness analysis.
    de Jong LA; Gout-Zwart JJ; van den Bosch M; Koops M; Postma MJ
    J Med Econ; 2019 Apr; 22(4):306-318. PubMed ID: 30614320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative safety and effectiveness of rivaroxaban versus VKAs in patients with venous thromboembolism. A Danish nationwide registry-based study.
    Sindet-Pedersen C; Langtved Pallisgaard J; Staerk L; Gerds TA; Fosbøl EL; Torp-Pedersen C; Gislason G; Olesen JB
    Thromb Haemost; 2017 Jun; 117(6):1182-1191. PubMed ID: 28300865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rivaroxaban versus standard anticoagulation for symptomatic venous thromboembolism (REMOTEV observational study): Analysis of 6-month outcomes.
    Gaertner S; Cordeanu EM; Nouri S; Faller AM; Frantz AS; Mirea C; Bilbault P; Ohlmann P; Le Ray I; Stephan D
    Int J Cardiol; 2017 Jan; 226():103-109. PubMed ID: 27806307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTE.
    Bounameaux H; Haas S; Farjat AE; Ageno W; Weitz JI; Goldhaber SZ; Turpie AGG; Goto S; Angchaisuksiri P; Nielsen JD; Kayani G; Schellong S; Mantovani LG; Prandoni P; Kakkar AK
    Thromb Res; 2020 Jul; 191():103-112. PubMed ID: 32422442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and Safety of Oral Anticoagulants in the Treatment of Acute Venous Thromboembolism: A Nationwide Comparative Cohort Study in France.
    Bertoletti L; Gusto G; Khachatryan A; Quignot N; Chaves J; Moniot A; Mokgokong R
    Thromb Haemost; 2022 Aug; 122(8):1384-1396. PubMed ID: 34983073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-vitamin K oral anticoagulants versus vitamin K antagonists in the treatment of venous thromboembolic disease.
    Voukalis C; Lip GY; Shantsila E
    Expert Opin Pharmacother; 2016 Oct; 17(15):2033-47. PubMed ID: 27667112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD-VTE patients.
    Haas S; Ageno W; Weitz JI; Goldhaber SZ; Turpie AGG; Goto S; Angchaisuksiri P; Dalsgaard Nielsen J; Kayani G; Zaghdoun A; Farjat AE; Schellong S; Bounameaux H; Mantovani LG; Prandoni P; Kakkar AK
    J Thromb Haemost; 2019 Oct; 17(10):1694-1706. PubMed ID: 31220403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abnormal uterine bleeding in VTE patients treated with rivaroxaban compared to vitamin K antagonists.
    De Crem N; Peerlinck K; Vanassche T; Vanheule K; Debaveye B; Middeldorp S; Verhamme P; Peetermans M
    Thromb Res; 2015 Oct; 136(4):749-53. PubMed ID: 26272306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do women with venous thromboembolism bleed more than men during anticoagulation? Data from the real-life, prospective START-Register.
    Palareti G; Legnani C; Antonucci E; Cosmi B; Falanga A; Poli D; Mastroiacovo D; Pengo V; Ageno W; Testa S
    Ther Adv Drug Saf; 2021; 12():20420986211062965. PubMed ID: 34987749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case fatality of bleeding and recurrent venous thromboembolism during, initial therapy with direct oral anticoagulants: a systematic review.
    Wu C; Alotaibi GS; Alsaleh K; Sean McMurtry M
    Thromb Res; 2014 Sep; 134(3):627-32. PubMed ID: 25047174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On-treatment Comparative Effectiveness of Vitamin K Antagonists and Direct Oral Anticoagulants in GARFIELD-VTE, and Focus on Cancer and Renal Disease.
    Haas S; Farjat AE; Pieper K; Ageno W; Angchaisuksiri P; Bounameaux H; Goldhaber SZ; Goto S; Mantovani L; Prandoni P; Schellong S; Turpie AGG; Weitz JI; MacCallum P; Cate HT; Panchenko E; Carrier M; Jerjes-Sanchez C; Gibbs H; Jansky P; Kayani G; Kakkar AK;
    TH Open; 2022 Oct; 6(4):e354-e364. PubMed ID: 36452204
    [No Abstract]   [Full Text] [Related]  

  • 14. DOACs Versus VKAs in Older Adults Treated for Acute Venous Thromboembolism: Systematic Review and Meta-Analysis.
    Chaudhary R; Pagali S; Garg J; Murad MH; Wysokinski WE; McBane RD
    J Am Geriatr Soc; 2020 Sep; 68(9):2021-2026. PubMed ID: 32441334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Analysis of All-Cause Health Care Resource Utilization and Costs Among Venous Thrombosis Patients Without Cancer Prescribed Apixaban or VKAs in France.
    Mokgokong R; Khachatryan A; Quignot N; Chaves J; Moniot A; Gusto G
    Adv Ther; 2022 Aug; 39(8):3766-3776. PubMed ID: 35767124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence.
    Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
    Clin Ther; 2016 Mar; 38(3):478-93.e1-16. PubMed ID: 26922297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bleeding and thrombotic complications during treatment with direct oral anticoagulants or vitamin K antagonists in venous thromboembolic patients included in the prospective, observational START2-register.
    Palareti G; Antonucci E; Legnani C; Mastroiacovo D; Poli D; Prandoni P; Tosetto A; Pengo V; Testa S; Ageno W;
    BMJ Open; 2020 Nov; 10(11):e040449. PubMed ID: 33247017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The economic implications of switching to rivaroxaban from enoxaparin plus vitamin K antagonist in the treatment of venous thromboembolism.
    Patel AA; Ogden K; Mody SH; Bookhart B
    J Med Econ; 2015 May; 18(5):323-32. PubMed ID: 25557176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using oral anticoagulants among chronic kidney disease patients to prevent recurrent venous thromboembolism: A systematic review and meta-analysis.
    Alhousani M; Malik SU; Abu-Hashyeh A; Poznanski NJ; Al-Hasan S; Roth DF; Alsharedi M; Mustafa B
    Thromb Res; 2021 Feb; 198():103-114. PubMed ID: 33310644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials.
    Kakkos SK; Kirkilesis GI; Tsolakis IA
    Eur J Vasc Endovasc Surg; 2014 Nov; 48(5):565-75. PubMed ID: 24951377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.